September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
Sotagliflozin: CV Benefit Seen in Patients with T2 Diabetes, Worsening Heart Failure
Sotagliflozin reduced CV death and hospitalization for HF in patients with T2D and acute symptomatic HF when given during or immediately after hospitalization.
Top Content 2020: Preventive Cardiology
The most popular features in preventive cardiology this year were interviews with thought leaders on management of diabetes, hypertension, and hypercholesterolemia.
Adherence to Mediterranean Diet Associated with Lower Rate of T2D in Women
A recent study showed women who adhered to a Mediterranean diet had a 30% lower rate of type 2 diabetes vs women who did not.
SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients
Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.
DAPA-CKD Investigator: "PCPs Should be First-line Prescribers of SGLT2 Inhibitors"
Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.
Professor John McMurray Highlights DAPA-CKD Trial Outcomes
DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.
Brigham and Women's Endocrinologist on Trends in Diabetes Management
Director of the Brigham Diabetes Program at the Brigham and Women's Hospital discusses the latest in diabetes management.
Once-weekly Semaglutide 2.0 mg Bests 1.0 mg Dose for A1c, Weight Reduction
Once-weekly semaglutide 2.0 mg vs 1.0 mg led to statistically significant, superior reductions in A1c and weight in type 2 diabetes patients not at goal, study finds.
DAPA-CKD Trial Findings Could Transform CKD Therapy
AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.
Higher Green Tea and Coffee Intake May Reduce Mortality Risk in Patients with T2D
A new study of Japanese adults with type 2 diabetes found dual consumption of green tea and coffee reduced mortality risk by >60%.
CLINICAL FOCUS COLLECTION: Preventive Cardiology
Preventive Cardiology Collection Table of Contents: Expert video interviews, short, clinical guideline-focused quizzes, facts at-a-glance slideshows, plus news.
Guideline-directed Weight Loss: 4 Questions for Primary Care Physicians
Rapidly rising obesity rates in the US threaten to reverse decades of effort against cardiometabolic disease. How well do you know what experts recommend for your at-risk patients?
The Obesity Paradox: How Real is It?
Carl "Chip" Lavie, MD, author of the original book titled, "The Obesity Paradox" explains the paradox of metabolic health in the obese, how it wanes, and an essential element to maintain it.
4 Questions for PCPs on Prevention and Management of Cardiometabolic Diseases
Waist circumference measures, complementary antihypertensives, appropriate exercise levels for T2D patients--test what you know about cardiometabolic risk and management.
Finerenone Slows Renal Decline, Improves CV Outcomes in FIDELIO-DKD
The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.
Managing Diabetes to Prevent Cardiovascular Disease: A Guideline Quiz
Diabetes is a primary risk factor for atherosclerotic cardiovascular disease. Find out how well you know the guideline recommendations for reducing that risk with the first of 4 quizzes.
DPP-4 Inhibitor Found to Boost Survival in T2D Patients with COVID-19
According to a new study, adults with T2D who were hospitalized with COVID-19 in northern Italy had a lower mortality rate when treated with sitagliptin.
Patients with T2D at Greater Risk for Vascular than Other Dementias
The association of vascular dementia with T2D is stronger than that of nonvascular or Alzheimer dementia, according to a study presented at EASD.
Type 2 Diabetes: Clinical Guidelines Concur on CV Risk Management
What do clinical guidelines from diabetes, cardiology, and endocrinology associations have in common? A case study quiz with an evidence-based answer explains.
FDA Puts Empagliflozin on Fast Track for Reduced Post-MI All-cause Mortality
Empagliflozin is now in FDA fast-track development for prevention of hospitalization for HF and reduced all-cause mortality in patients, with/without diabetes, post-AMI.
Moderate Alcohol Consumption Tied to Hypertension Risk in Diabetes
A new research article found moderate and heavy alcohol intake were associated with hypertension in patients with type 2 diabetes.
Weight Loss Shown to be Strongest Predictor of Type 2 Diabetes Remission
A new research article showed that after 1 year of weight loss intervention, 46% of patients with type 2 diabetes achieved remission.
10-year Study: Usual A1c >7% Raises Cardiovascular Risk in Type 2 Diabetes
The risk of having a CVD-related event is increased by 21% for every 1% increase in usual A1c >7% in patients with type 2 diabetes, a new study finds.
SGLT2 Inhibitors and Cardiovascular Outcomes Trials: 4 Questions
Refresh your memory on findings from the EMPA-REG OUTCOME, CANVAS, CREDENCE, and DECLARE-TIMI cardiovascular outcomes trials on SGLT2 inhibitors.
Diana Isaacs, PharmD: An Overview of Insulin Affordability in 2020
Insulin affordability is an ongoing discussion topic for patients with diabetes and their care providers. The already difficult issue has been further compounded by the ongoing COVID-19 pandemic.
Metabolic Effects Comparable with Roux-en-Y vs Diet in Type 2 Diabetes
In patients with obesity and type 2 diabetes, metabolic improvements were similar after weight loss induced by surgery or a low-calorie diet.
Obesity Could Stymie Preventive Cardiology Efforts
VIDEO: Obesity is a chronic, relapsing disease that threatens to neutralize, even reverse, years of progress in reducing CVD-related death. Ted Kyle, RPh, explores.
VIDEO: CVD Risk Reduction in Primary Care: Diabetes
Jorge Plutzky, MD, director of the Preventive Cardiology Program at Brigham and Women's Hospital, discusses the insidious role diabetes plays in cardiovascular disease.
SGLT2 Inhibitors & GLP-1 Receptor Agonists: Differences, Similarities, Patient Selection
SGLT2 inhibitors and GLP-1 receptor agonists are changing the type 2 diabetes treatment paradigm. We summarize the most recent data here and offer guidance on patient benefits.
New Insights into the Physiology of Obesity - What They Mean for Primary Care
The physiology of obesity makes weight loss, by itself, unlikely to successfully treat the chronic disease of obesity. What does this mean for primary care clinical strategies?